Condiciones de Salud"Manchas ante los ojos" generalmente se refieren a moscas volantes—pequeñas formas sombrías que parecen desplazarse por el campo visual. Estas pueden verse como puntos, hilos, telarañas o motas, y son más notorias al mirar una superficie brillante y uniforme como el cielo o una pared en blanco. Las moscas volantes son causadas por pequeños grupos de colágeno o células dentro del humor vítreo, la sustancia gelatinosa que llena el interior del globo ocular.
Las moscas volantes son muy comunes y generalmente benignas, especialmente como parte del proceso natural de envejecimiento. Con la edad, el vítreo se encoge y se vuelve más líquido, lo que lleva al desprendimiento vítreo posterior (PVD), donde el vítreo se separa de la retina y causa moscas volantes. Sin embargo, los aumentos repentinos de moscas volantes, especialmente si van acompañados de destellos de luz, una cortina oscura sobre la visión, o pérdida de visión, pueden indicar un desgarro o desprendimiento de retina, lo cual requiere atención médica inmediata.
Otras causas de moscas volantes incluyen traumatismo ocular, inflamación (uveítis), retinopatía diabética, o cirugías oculares, como la extracción de cataratas. En casos raros, las moscas volantes también pueden resultar de infecciones oculares o sangrado dentro del ojo.
Cuándo consultar a un médico:
Busque evaluación inmediata si las moscas volantes aparecen de repente, aumentan rápidamente, o van acompañadas de destellos de luz, dolor ocular, o cualquier pérdida de visión periférica o central. Estas pueden indicar daño retinal u otras afecciones oculares graves.
Ashwagandha (Withania somnifera) is an Ayurvedic adaptogen with multiple RCTs and a 2024 meta-analysis confirming significant cortisol reductions in stressed individuals via HPA axis modulation. It has been studied in the context of adrenal steroidogenesis disorders including non-classical adrenal hyperplasia, where it reduced multiple adrenal precursor steroids. A published case report (PMC12824993) documented that high-dose ashwagandha caused HPA axis suppression producing Cushingoid features, demonstrating its potent cortisol-modulating activity. At 300–600 mg/day standardized extract, it reduces cortisol by approximately 20–28%.
HMR lignan (7-hydroxymatairesinol), derived from Norway spruce bark, is used alongside melatonin as a natural treatment approach for Cushing's disease. Like SDG, HMR inhibits cortisol-producing enzymes (3-beta-HSD and aromatase) by converting to enterolactone in the gut. University of Tennessee veterinary medicine recommends both HMR and SDG lignans for Cushing's treatment, citing equivalent efficacy in reducing cortisol levels. HMR has superior bioavailability compared to SDG, as gut conversion to enterolactone is more rapid and complete.
Melatonin has been studied for its ability to inhibit enzymes involved in cortisol biosynthesis in the adrenal glands, making it relevant to Cushing's disease management. Studies show melatonin circadian secretion is significantly lower in patients with pituitary- or adrenal-dependent Cushing's syndrome compared to healthy controls. Research (Pawlikowski et al., 2002) demonstrated that nightly administration of 2 mg melatonin increased the DHEA-S-to-cortisol ratio after 6 months. University of Tennessee veterinary studies found melatonin combined with lignans reduces adrenal steroid concentrations in Cushing's cases.
Phosphatidylserine (PS) is a phospholipid that modulates HPA axis activity at the pituitary level, blunting cortisol release. Clinical trials show that 600–800 mg/day significantly reduces cortisol response to stress, with one study finding up to a 35% reduction in cortisol area-under-the-curve. A double-blind placebo-controlled crossover study (PMC2503954; n=10 healthy males, 600 mg/day for 10 days) confirmed blunted cortisol response before and during exercise-induced stress. While studied primarily in stress-induced hypercortisolism rather than pituitary-driven Cushing's disease, PS is used clinically as an adjunct to reduce cortisol burden.
Secoisolariciresinol Diglucoside (SDG), the primary lignan from flaxseed hulls, is studied for Cushing's disease due to its ability to inhibit steroidogenic enzymes (3-beta-HSD and aromatase) involved in cortisol and estradiol production. University of Tennessee veterinary research found SDG lignans combined with melatonin lowered cortisol concentrations in dogs with Cushing's. The gut microbiota converts SDG to enterolactone and enterodiol, the active mammalian lignans. Both HMR and SDG lignans are recommended by the University of Tennessee for Cushing's treatment.
Retinoic acid, the active metabolite of vitamin A, has been studied in multiple preclinical and clinical trials specifically for Cushing's disease. It inhibits ACTH production by pituitary corticotroph tumor cells via POMC transcription suppression and exhibits antiproliferative effects on those tumors. A prospective multicenter human trial showed 43% of 7 patients normalized urinary free cortisol (UFC) at doses of 10–80 mg/day for 6–12 months. A second prospective trial of 16 patients found 25% achieved eucortisolemia and all showed cortisol reduction.
Vitamin D3 (cholecalciferol) supplementation has been specifically studied in Cushing's disease patients, who have significantly higher rates of vitamin D deficiency than matched controls. A clinical study (Nutrients 2022; n=50 active CD patients) found that vitamin D deficiency severity correlated with urinary free cortisol levels. Six weeks of cholecalciferol supplementation (150,000 IU load) significantly improved insulin sensitivity, raised 25(OH)D, lowered PTH, and reduced total cholesterol in CD patients. The study recommends vitamin D supplementation as a standard part of CD management.
Volver